消癌平注射液直肠给药联合常规化疗治疗上皮性卵巢癌的临床观察

发布时间：2018-03-12 14:25

本文选题：消癌平注射液　切入点：直肠给药　出处：《中国药房》2015年20期 　论文类型：期刊论文

【摘要】：目的:观察消癌平注射液直肠给药联合常规化疗治疗上皮性卵巢癌的临床疗效和安全性。方法:选择确诊为上皮性卵巢癌的初诊患者60例,按入院顺序随机分为观察组和对照组各30例。所有患者均接受紫杉醇+卡铂(TC)化疗方案,共4~6个疗程。其中,对照组患者接受TC 3周化疗方案,即紫杉醇175 mg/m2,静脉滴注3 h+卡铂AUC 5~7.5,静脉滴注1 h。观察组在此基础上,再经直肠给予消癌平注射液,每次20~30 ml,每日1次,每2周1个周期。比较两组患者的临床有效率、1年无进展生存率和中位无进展生存期,以及不良事件发生率。结果:观察组的有效率为83.33%,高于对照组的53.33%,差异有统计学意义(χ2=13.20,P0.05);观察组的1年无进展生存率为86.67%,中位无进展生存期为11.3个月,对照组分别为63.33%和7.2个月,组间比较差异有统计学意义(P0.01或P0.05)。两组不良事件发生率差异无统计学意义(χ2=0.53,P=0.47)。结论:消癌平注射液直肠给药联合常规化疗治疗上皮性卵巢癌,疗效良好,安全性高,患者1年无进展生存率高,中位无进展生存期长。
[Abstract]:Objective: to observe the clinical efficacy and safety of rectal administration combined with conventional chemotherapy in the treatment of epithelial ovarian cancer. Methods: 60 patients with epithelial ovarian cancer were selected. The patients were randomly divided into observation group (n = 30) and control group (n = 30). All patients were treated with paclitaxel carboplatin (TCc) regimen for a total of 4 ~ 6 courses. That is, paclitaxel 175mg / m2, carboplatin AUC 57.5% iv for 3 h and intravenous drip 1 h. On this basis, the observation group was given Xiaoyangping injection via rectum, 20ml / day, once a day. The clinical effective rate, 1 year progression-free survival rate and median progression-free survival time were compared between the two groups every 2 weeks. Results: the effective rate of observation group was 83.33, higher than that of control group 53.33, the difference was statistically significant (蠂 ~ 2 ~ 2 ~ (13.20) P _ (0.05)), the 1-year progression-free survival rate of observation group was 86.67, the median progression-free survival time was 11.3 months, and that of control group was 63.33% and 7.2 months, respectively. There was no significant difference in the incidence of adverse events between the two groups (蠂 ~ 2 / 0. 53). Conclusion: the treatment of epithelial ovarian cancer by rectal administration of Xiaoyanping injection combined with routine chemotherapy has good curative effect and high safety. The 1-year progression-free survival rate was high and the median progression-free survival was long.
【作者单位】：黑龙江中医药大学附属第一医院;
【分类号】：R737.31

【参考文献】